

## **Technology Appraisal Committee Meeting (Committee A)**

**Minutes:** Confirmed

**Date and Time:** Wednesday 29<sup>th</sup> July 2015, 10.00am – 2.00pm

**Venue:** Prospero House, 241 Borough High Street, London SE1 1GA

<b>Present:</b>	1. Dr Jane Adam	Present for all notes
	2. Professor Iain Squire	Present for all notes
	3. Dr Anne McCune	Present for all notes
	4. Mr Adrian Griffin	Present for all notes
	5. Dr Mohit Misra	Present for all notes
	6. Dr Eldon Spackman	Present for all notes
	7. Dr Nerys Woolacott	Present for all notes
	8. Professor Olivia Wu	Present for all notes
	9. Dr Brian Shine	Present for all notes
	10. Mr David Thomson	Present for all notes
	11. Mrs Pamela Rees	Present for all notes
	12. Mrs Sarah Parry	Present for all notes
	13. Dr John Watkins	Present for all notes
	14. Dr Graham Ash	Present for all notes
	15. Mr Stephen Sharp	Present for all notes

### **In attendance:**

Meindert Boysen	Programme Director, National Institute for Health and Care Excellence	Present for all notes
Janet Robertson	Associate Director, National Institute for Health and Care Excellence	Present for all notes
Bijal Joshi	Project Manager, National Institute for Health and Care Excellence	Present for all notes
Marcia Miller	Technology Appraisal Administrator, National Institute for Health and Care Excellence	Present for all notes
Pilar Pinilla - Dominguez	Technical Analyst, National Institute for Health and Care Excellence	Present for all notes

Zoe Charles	Technical Adviser, National Institute for Health and Clinical Excellence	Present for notes all notes
-------------	---	-----------------------------

### **Evidence Review Group**

Professor Adrian Bagust	Liverpool reviews and implementation group	Present for notes 1-15
Nigel Fleeman	Liverpool reviews and implementation group	Present for notes 1-15

### **Non-public observers:**

Nejoua Belkaab	Ministry of Health Morocco - Delegate	Present for notes all notes
David Coombs	NICE, Corporate office	Present for notes all notes
Chems Eddouha	Ministry of Health	Present for notes all notes
Khassouani	Morocco - Delegate	
Nazih El Kouartey	Ministry of Health	Present for notes all notes
	Morocco - Delegate	
Rishi Mandavia	Liverpool review and implementation group	Present for notes all notes

## **Notes**

### **Welcome**

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of pembrolizumab for treating advanced melanoma after disease progression with ipilimumab [ID760]
2. The Chair informed the Committee of the non-public observers at this meeting: Nejoua Belkaab, David Coombs, Chems Eddouha Khassouani, Nazih El Kouartey and Rishi Mandavia.
3. Apologies were received from Dr Jeremy Braybrooke, Dr Gerardine Bryant, Ellen Rule and Andrew England.

### **Any other Business**

4. None

### **Notes from the last meeting**

5. The minutes were agreed

## Appraisal of pembrolizumab for treating advanced melanoma after disease progression with ipilimumab [ID760]

### Part 1 – Open session

6. The Chair welcomed the invited experts: Dr Pippa Corrie, Dr Louise Fearfield, and Kathryn Silvester-Eccles to the meeting and they introduced themselves to the Committee.
7. The Chair welcomed company representatives from Merck, Sharpe and Dohme to the meeting.
8. The Chair asked all Committee members to declare any relevant interests

Dr Jane Adam, Professor Iain Squire, Dr Anne McCune  
Mr Adrian Griffin, Dr Mohit Misra, Dr Eldon Spackman, Dr Nerys Woolacott, Professor Olivia Wu, Dr Brian Shine, Mr David Thomson  
Mrs Pamela Rees, Mrs Sarah Parry, Dr John Watkins, Dr Graham Ash  
Mr Stephen Sharp all declared that they knew of no personal specific pecuniary interest, personal non-specific pecuniary interest, non-personal specific pecuniary interest, non-personal non-specific pecuniary interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of pembrolizumab for treating advanced melanoma after disease progression with ipilimumab.

- 8.1. Dr Paul Robinson declared a personal specific pecuniary interest he is employed by Merck Sharp and Dohme, the company of the technology  
9.2.1 It was agreed that this declaration would prevent Dr Paul Robinson from participating and he was absent from the meeting.
9. The Chair asked all NICE Staff to declare any relevant interests.
  - 9.1. All declared that they knew of no personal specific pecuniary interest, personal non-specific pecuniary interest, non-personal specific pecuniary interest, non-personal non-specific pecuniary interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of pembrolizumab for treating advanced melanoma after disease progression with ipilimumab.
10. The Chair asked all other invited guests, ERG and invited experts, not including observers) to declare their relevant interests.
  - 10.1. Professor Adrian Bagust, Dr Louise Fairfield, Nigel Fleeman, Kathryn Silvester-Eccles all declared that they knew of no personal specific pecuniary interest, personal non-specific pecuniary interest, non-personal specific pecuniary interest, non-personal non-specific pecuniary interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of pembrolizumab for treating advanced melanoma after disease progression with ipilimumab.

- 10.2. Dr Pippa Corrie declared a personal specific pecuniary interest as she has received payment for attendance at Merck Advisory Boards relating to pembrolizumab and management of melanoma.
  - 10.2.1. It was agreed that this declaration would not prevent Dr Pippa Corrie from participating in this section of the meeting
11. The Chair introduced the lead team, Dr John Watkins, Mr David Thomson and Dr Eldon Spackman who gave presentations on the clinical effectiveness and cost effectiveness of pembrolizumab for treating advanced melanoma after disease progression with ipilimumab.
12. The Committee then discussed the clinical effectiveness, patient perspective and cost effectiveness of pembrolizumab for treating advanced melanoma after disease progression with ipilimumab on the basis of the evidence before them, and potential equality issues raised in this appraisal. They sought clarification and advice from the experts present. The discussions included:
  - 12.1. The current clinical management of advanced (unresectable or metastatic) melanoma in the NHS, the place of pembrolizumab within the treatment pathway and the relevant comparators for pembrolizumab
  - 12.2. The clinical need of people with advanced melanoma after progression with ipilimumab and, for BRAF V600 mutation-positive disease, a BRAF or MEK inhibitor
  - 12.3. The key clinical evidence for pembrolizumab from the KEYNOTE-002 trial which included people with advanced melanoma after progression with ipilimumab and, for BRAF V600 mutation-positive disease, after ipilimumab and a BRAF or MEK inhibitor
  - 12.4. The cost-effectiveness evidence, the results from the company's economic analysis and the critique and exploratory analyses from the evidence review group
  - 12.5. The innovative nature of pembrolizumab and whether pembrolizumab met all the criteria to be considered a life-extending, end-of-life treatment and whether the evidence presented was plausible, objective and robust enough to support it.
  - 12.6. Whether pembrolizumab could be considered a cost-effective use of NHS resources.
13. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
14. The Chair explained that "representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)" and all public attendees left the meeting.
15. The Chair then thanked the experts, company representatives and academic group for their attendance, participation and contribution to the appraisal and they left the meeting.

## **Part 2 – Closed session**

16. The Committee continued to discuss the clinical and cost effectiveness of pembrolizumab for treating advanced melanoma after disease progression with ipilimumab [ID760]
17. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

## **Date, time and venue of the next meeting**

18. Wednesday 26<sup>th</sup> August 2015, 10am at Prospero House, 241 Borough High Street, London SE1 1GA.